Since its beginning, the brand value of MenaQ7® was built, step by step, on critical pillars that eventually became the backbone of the K2 category as we know it today. Renowned for its proven ability to support bone and cardiovascular health, Vitamin K2 continues to gain recognition, and the future shines brighter than ever for this potent molecule. Join us on this exciting journey with MenaQ7®, as we unveil its new brand identity.
With emerging research, it becomes crucial to further explore the expanding role of vitamin K2 in promoting foundational health at all stages of life, and at Gnosis, we are looking beyond the clinically proven benefits of Vitamin K2 for bone and heart health. This evolution marks the perfect time for us to redefine the MenaQ7® brand identity, reflecting our commitment to exploration and discovery.
A Vitamin K2 Evolution
The refreshed logo, featuring a magnifying glass, encapsulates the spirit of curiosity, an essential attribute to usher Vitamin K2 into the future — illuminating new indications with technological innovations that will unlock new finished product applications. Other new elements are the logo’s colors and tagline. The new logo emphasizes Gnosis’ dedication to natural processes that leave minimal impact on the environment.
Through this new brand identity, we emphasize an unwavering commitment to transforming health through scientifically backed, natural solutions. Simply put, MenaQ7® is the K2 brand that goes above and beyond and is the choice for brands that aspire for more. Experience it firsthand with our captivating video.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...